[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indolent-b-cell-non-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indolent-b-cell-non-hodgkin-lymphoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,93,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100545777","phase-2-reduced-dose-radiotherapy-for-the-treatment-of-indolent-non-hodgkin-lymphoma-100545777",false,"NCT06386315","Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma","MC230808 Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological confirmation of indolent B-cell lymphoma that can include any of the following:\n\n  * Follicular lymphoma (grade 1 or 2 or 3A)\n  * Marginal zone lymphoma (nodal or extranodal)\n  * Follicle center lymphoma\n* Any stage disease\n* Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items\n* Confirmation from radiation oncologist of suitability to participate in study\n\nExclusion Criteria:\n\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Women of childbearing potential who are unwilling to employ adequate contraception\n* T-cell lymphoma\n* Receiving treatment for small and chronic lymphocytic lymphoma\n* Grade 3B follicular lymphoma","ALL","18 Years",{"count":19,"type":20},112,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and\u002For effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.",[26,27,28,29,30],"Indolent B-Cell Non-Hodgkin Lymphoma","Recurrent Indolent B-Cell Non-Hodgkin Lymphoma","Refractory Indolent B-Cell Non-Hodgkin Lymphoma","Recurrent Indolent Non-Hodgkin Lymphoma","Refractory Indolent Non-Hodgkin Lymphoma","RECRUITING","2026-04-17",{"date":34,"type":35},"2026-04-22","ACTUAL",{"date":37,"type":35},"2024-05-15",{"date":39,"type":20},"2027-05-30",{"name":41,"class":42},"Mayo Clinic","OTHER",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100557911","phase-1-synkir-310-for-relapsedrefractory-b-nhl-100557911","NCT06544265","SynKIR-310 for Relapsed\u002FRefractory B-NHL","A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Adult 18 years of age and older.\n* Histologically confirmed diagnosis of B-NHL before enrollment.\n* Must have received prior CAR T or were unwilling\u002Funable to receive prior CAR T.\n* Must have refractory or relapsed disease after receiving 2 prior lines of therapies.\n* If relapsed\u002Frefractory post-auto-SCT, then must have undergone auto-SCT at least 6 months prior to enrollment.\n* If relapsed\u002Frefractory disease after allogeneic stem cell transplant (allo SCT) then must have undergone allo-SCT at least 6 months prior to enrollment and without evidence of graft versus host disease, and expectation to remain off immunosuppressive therapy through duration of trial\n* Measurable disease at time of enrollment: At least one measurable lesion per Lugano Response Criteria (Cheson et al., 2014) or measurable disease per IWWM-11 response criteria (Treon 2023) for Waldenström macroglobulinemia patients.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* Previously treated with any investigational agent within 30 days prior to screening.\n* Any previous or concurrent malignancy, with the following exceptions:\n\nAdequately treated non-melanoma skin cancer such as basal cell or squamous cell carcinoma; carcinoma-in-situ (e.g., cervix, bladder, breast) treated curatively and without evidence of recurrence for at least 3 years prior to enrollment or adequately treated melanoma skin cancer in-situ; any other malignancy which has been completely treated and remains in complete remission for ≥ 5 years prior to enrollment. Completely treated prostate cancer with prostate-specific antigen (PSA) level \\\u003C 1.0 may also be permitted.\n\n* Use of systemic immunosuppressive drugs within 4 weeks prior to study entry, or anticipated use of systemic immunosuppressive agents through end of study, with the exception of non-T cell targeting agents prior to leukapheresis\n* Known immunodeficiency disease , with the exception of hypoglobulinemia\n* History or presence of active or clinically relevant primary central nervous system (CNS) disorder, such as seizure, encephalopathy, cerebrovascular ischemia\u002Fhemorrhage, cerebellar disease, or any autoimmune disease with CNS involvement. For primary CNS disorders that have recovered or are in remission, participants without recurrence within 2 years of planned study enrollment may be included.\n* Uncontrolled hypertension, history of myocarditis or congestive heart failure, unstable angina, serious uncontrolled cardiac arrhythmia, or myocardial infarction within 6 months prior to study entry.\n* Any active uncontrolled systemic fungal, bacterial or viral infection.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":52,"type":20},36,[54],"PHASE1","This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed\u002Frefractory B-NHL.",[57,58,59,60,61,62,26,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"B Cell Lymphoma","NHL, Adult","Mantle Cell Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Aggressive B-Cell Non-Hodgkin Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma","HGBL With MYC and BCL2 and\u002For BCL6 Rearrangements","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma","Large B-cell Lymphoma","T-Cell\u002FHistiocyte Rich Lymphoma","Non-hodgkin Lymphoma,B Cell","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Epstein-Barr Virus Positive DLBCL, Nos","Follicular Lymphoma Grade 3B","DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation","High Grade B-Cell Lymphoma, Not Otherwise Specified","Follicular Lymphoma Grade 3","Marginal Zone Splenic Lymphoma","DLBCL","Waldenstrom Macroglobulinemia","Waldenstrom Macroglobulinaemia","2026-04-08",{"date":84,"type":35},"2026-04-14",{"date":86,"type":35},"2024-11-01",{"date":88,"type":20},"2028-12",{"name":90,"class":91},"Verismo Therapeutics","INDUSTRY",5,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100329618","phase-1-a-study-of-bi-1206-in-combination-with-rituximab-with-or-without-acalabrutinib-in-subjects-with-indolent-b-cell-nhl-100329618","NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","Phase 1\u002F2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab","Inclusion Criteria:\n\n1. Are ≥ 18 years of age by initiation of study treatment.\n2. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)\n3. Have measurable nodal disease\n4. Are willing to undergo lymph node biopsies or biopsies of other involved tissue\n5. Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists\n6. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen\n7. Have a life expectancy of at least 12 weeks\n8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n9. Have CD20+ malignancy\n10. Have hematological and biochemical indices within prespecified ranges\n\nExclusion Criteria:\n\n1. Have had an allogenic bone marrow or stem cell transplant within 12 months\n2. Have presence of active chronic graft versus host disease\n3. Have current leptomeningeal lymphoma or compromise of the central nervous system\n4. Have transformed lymphoma from a pre-existing indolent lymphoma\n5. Have Waldenstrom's Macroglobulinemia or FL grade 3B,\n6. Need systemic doses of prednisolone \\>10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.\n7. Have known or suspected hypersensitivity to rituximab or BI-1206\n8. Have cardiac or renal amyloid light-chain amyloidosis\n9. Have received any of the following:\n\n   1. Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206\n   2. Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks\n   3. Immunotherapy within 8 weeks\n   4. Previous lines of treatment containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib\n10. Have ongoing toxic manifestations of previous treatments.\n11. Have the ability to become pregnant (or already pregnant or lactating\u002Fbreastfeeding).\n12. Have had major surgery from which the subject has not yet recovered.\n13. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.\n14. Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).\n15. Have an active, known or suspected autoimmune disease.\n16. Have concurrent congestive heart failure, prior history of class III\u002F IV cardiac disease (New York Heart Association \\[NYHA\\])\n17. Have current malignancies of other types",{"count":101,"type":20},140,[54,23],"Phase 1\u002F2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab",[26],"2025-04-23",{"date":107,"type":35},"2025-04-24",{"date":109,"type":35},"2018-05-16",{"date":111,"type":20},"2026-09-30",{"name":113,"class":91},"BioInvent International AB",27,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100551522","phase-2-ga-68-cxcr4-petct-in-indolent-b-cell-lymphoma-100551522","NCT06461182","Ga-68-CXCR4 PET\u002FCT in Indolent B-cell Lymphoma","Ga-68-CXCR4 PET\u002FCT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma","PentixaFor","Inclusion Criteria:\n\n* The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL\u002FSLL, mantle cell lymphoma.\n* Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.\n* Able to lie flat for at least 30 minutes.\n* Signing the subject consent form.\n* ECOG grade 0-2.\n* The timing of F-18-FDG usage in this trial follows the \"Lymphoma Treatment Principles\" of our institution.\n\nExclusion Criteria:\n\n* Pregnant woman\n* Severe renal impairment (eGRF\\\u003C 30ml\u002Fmin)\n* Known or suspected allergy to radiopharmaceuticals\n* Concurrent or previous diagnosis of malignancies other than lymphoma\n* Inability to undergo the necessary PET scan procedure\n* Refusal or unwillingness to sign the informed consent form\n* Severe medical conditions (severe disabilities, mental disorders)","20 Years","100 Years",{"count":126,"type":20},15,[23],"This study explores the efficacy of Ga-68-PentixaFor PET\u002FCT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.",[26],[131,132],"Ga-68-CXCR4 PET\u002FCT","indolent B-cell lymphoma","2024-06-11",{"date":135,"type":35},"2024-06-14",{"date":137,"type":35},"2024-04-29",{"date":139,"type":20},"2027-04",{"name":141,"class":42},"Koo Foundation Sun Yat-Sen Cancer Center",1]